Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BCAB
Upturn stock ratingUpturn stock rating

Bioatla Inc (BCAB)

Upturn stock ratingUpturn stock rating
$0.4
Last Close (24-hour delay)
Profit since last BUY-24%
upturn advisory
SELL
SELL since 2 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: BCAB (1-star) is a SELL. SELL since 2 days. Profits (-24.00%). Updated daily EoD!

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

4 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $8.33

1 Year Target Price $8.33

Analysts Price Target For last 52 week
$8.33Target price
Low$0.24
Current$0.4
high$2.52

Analysis of Past Performance

Type Stock
Historic Profit -77.47%
Avg. Invested days 24
Today’s Advisory SELL
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 22.43M USD
Price to earnings Ratio -
1Y Target Price 8.33
Price to earnings Ratio -
1Y Target Price 8.33
Volume (30-day avg) 4
Beta 0.91
52 Weeks Range 0.24 - 2.52
Updated Date 06/30/2025
52 Weeks Range 0.24 - 2.52
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.22

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -610%

Management Effectiveness

Return on Assets (TTM) -65.79%
Return on Equity (TTM) -246.21%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -9376434
Price to Sales(TTM) 2.04
Enterprise Value -9376434
Price to Sales(TTM) 2.04
Enterprise Value to Revenue 2.25
Enterprise Value to EBITDA 0.31
Shares Outstanding 58418100
Shares Floating 45152550
Shares Outstanding 58418100
Shares Floating 45152550
Percent Insiders 10.66
Percent Institutions 32.91

Analyst Ratings

Rating 2
Target Price 8.33
Buy 1
Strong Buy 2
Buy 1
Strong Buy 2
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Bioatla Inc

stock logo

Company Overview

overview logo History and Background

BioAtla, Inc. was founded in 2007 and is a global biotechnology company focused on developing conditionally active antibody therapeutics for cancer treatment. It has evolved from a research-focused organization to a clinical-stage company with a portfolio of innovative therapeutic candidates.

business area logo Core Business Areas

  • Conditionally Active Biologics (CABs) Development: BioAtla specializes in developing CABs, which are designed to be active in the tumor microenvironment, reducing off-target effects and improving safety.
  • Clinical Trials: The company conducts clinical trials to evaluate the safety and efficacy of its CAB candidates in various cancer types.
  • Research and Development: BioAtla invests in ongoing research and development to expand its CAB platform and discover new therapeutic targets.

leadership logo Leadership and Structure

BioAtla is led by a team of experienced biotechnology executives. The organizational structure includes research, development, clinical operations, and administrative functions.

Top Products and Market Share

overview logo Key Offerings

  • BA3011: BA3011 is a CAB-AXL-ADC (antibody-drug conjugate) targeting AXL-expressing tumors. Currently in clinical development. Competitors include companies developing similar ADCs or AXL-targeted therapies, but specific market share data is unavailable due to the developmental stage.
  • BA3021: BA3021 is a CAB-ROR2-ADC targeting ROR2-expressing tumors. Currently in clinical development. Competitors include companies developing similar ADCs or ROR2-targeted therapies. No current revenue due to product in clinical trials. Market share unavailable at the current clinical trial phase.

Market Dynamics

industry overview logo Industry Overview

The biotechnology industry is highly competitive and rapidly evolving, with significant investment in cancer therapeutics. There is a strong demand for novel therapies that can improve patient outcomes while minimizing side effects.

Positioning

BioAtla is positioned as an innovator in the field of conditionally active biologics. Its CAB platform offers a potential competitive advantage by enabling the development of targeted therapies with improved safety profiles.

Total Addressable Market (TAM)

The global oncology market is estimated to be hundreds of billions of dollars. BioAtla is positioned to capture a portion of this market with its targeted cancer therapies, particularly if its CAB platform proves successful in clinical trials. TAM for CAB-based therapies is difficult to quantify precisely but represents a growing segment within the broader oncology market.

Upturn SWOT Analysis

Strengths

  • Proprietary CAB technology platform
  • Pipeline of novel therapeutic candidates
  • Experienced leadership team

Weaknesses

  • Dependence on clinical trial outcomes
  • Limited commercialized products
  • High cash burn rate

Opportunities

  • Potential partnerships with larger pharmaceutical companies
  • Expansion of CAB platform to new therapeutic areas
  • Positive clinical trial results leading to regulatory approvals

Threats

  • Clinical trial failures
  • Competition from established pharmaceutical companies
  • Regulatory hurdles

Competitors and Market Share

competitor logo Key Competitors

  • MRTX
  • ARRY
  • NKTR
  • IMVT

Competitive Landscape

BioAtla's advantage lies in its CAB technology, allowing for more targeted and potentially safer cancer therapies. Disadvantages include dependence on clinical trial outcomes and competition from larger, established companies.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is characterized by pipeline advancement and technology development.

Future Projections: Future growth is dependent on clinical trial success and potential commercialization of CAB-based therapies. Analyst estimates are available from various financial data providers.

Recent Initiatives: Recent initiatives include advancing clinical trials, expanding the CAB platform, and seeking partnerships.

Summary

BioAtla is a clinical-stage biotech firm with a novel CAB platform that can potentially yield a more targeted, safer cancer treatment option. Its clinical trial progress is critical, and failure can be detrimental to its stock. The firm's CAB technology and experienced leadership position it well for potential future growth within the oncology sector, but will need to watch out for regulatory hurdles. Partnering with a larger pharmaceutical company may also be a pathway to success.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • BioAtla Investor Relations
  • SEC Filings (10-K, 10-Q)
  • Market Reports
  • Analyst Reports

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise. Investment decisions should be based on individual research and consultation with a financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Bioatla Inc

Exchange NASDAQ
Headquaters San Diego, CA, United States
IPO Launch date 2020-12-16
Co-Founder, CEO & Chairman Dr. Jay M. Short Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 61
Full time employees 61

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.